drugset / Trial / NCT00811759

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

NCT00811759

Phase 1/2 Unknown 58 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Open-labelTreatment

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with temozolomide may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib together with temozolomide in treating patients with stage III or stage IV melanoma.

Timeline

Start
2007-06
Primary completion
2009-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule Oral
Subject Temozolomide Small molecule Oral

Indications